Abstract
A prospective non-randomized study was conducted to determine the effectiveness, toxicity and tolerance of Methotrexate (MTX) as initial therapy in patients with advanced head and neck squamous cell carcinoma (H & N Cancer). Eighty patients were given two courses of 100 mg/m2 MTX by i. v. route as abolus at fifteen days interval without Leucovorin rescue. Patients were evaluated for response two weeks after the second course. Response rate was as high as 26.6% CR (Complete Regression) and 42.6% PR (Partial regression) in primary lesion, while it was 8% CR and 42.6% PR in secondaries (regional lymph nodes). This schedule seems to be effective, cheap, well tolerable and can be used on out-patient basis.
Similar content being viewed by others
References
Advani SH, Mehta AR, Rao RS et al Moderate dose Methotrexate in head and neck Cancer.Oncology 1981; 38:329–333.
Bahadur S, Role of Chemotherapy in advanced Head and neck Cancer.Indian Journal of Otolaryngology. 1984; 36:31–34.
Bertino, JR, NMosher MD, De Conti RC, Chemotherapy of Cancer of head and Neck.Cancer 1973; 31:1141.
Buechlor M, Mukherji B, Chasin W, Nathanson L.,—High dose Methotrexate with and without BCG therapy in advanced head and neck Malignancy.Cancer 1979; 43: 1095 1100.
DE Conti RC, Schoenfeld D, A ran domized prospective comparison of intermittent Methotrexate, Methotrexate with Leucovorin, and a Methotrexate combination in head and neck Cancer.Cancer 1981; 48: 1061–1072.
Elias GE; Chretien PB, Monnard G et al—Chemotherapy prior to local therapy in advanced squamous cell carcinoma of head and neck.Cancer 1979; 43: 1025–1031.
Frei E, Blum RH, Pitman SW, et al—High dose Methotrexate with Leucovorin rescue. A retionale and spectrum of anti-tumour activity. Am. J. Med. 1980; 68:370.
Hong WK, Stanley MS, Bhutani R. et al—Induction chemotherapy in advanced squamous Head & Neck carcinoma with High dose Cis-Platinum and Bleomycin infusion.Cancer 1979; 44: 19–25.
Hanham IWF, Newton KA, Westbury G, Seventy five cases of solid tumours treated by modified quadruple chemotherapy regimen, Brit. J.Cancer 1971 ;25–642.
Hong WK, Steven Schaefer, Brain issel et al. A prospective Randomized Trial of Methotrexate versus Cis-platinum in the treatment of recurrent squamous cell carcinoma of the head and neck,Cancer 1983 ; 51:206–210.
Methotrexate Antimetabolic agent for Cancer Chemotherapy. New York American Cynamid Company 1970;823R: 56.
Pointon RCS, Askill CS, Hunter RD, Wilkinson PM.—Treatment of advanced head and neck Carcinoma with synchronus irradiation and Methotrexate.Cancer Treat. Rep. 1981; 65: (Suppl-I), 145–148.
Price LA, Calvert BT, Dalley AH et al. Improved results in combination chemotherapy of head and neck Cancer using a kinetically based approach: A randomized study with and without Adriamycin.Oncology 1978; 35: 36.
Paul Y Holove, Robert MB, Donald AG, Goephest H, et al—Combination Chemotherapy of head and neck cancer.Cancer 1978; 42: 1661–1669.
Price LA, Hill BT, Principles of Chemotherapy in head and neck Cancer. In Ballantyne J., Groves J. Scott-Brown’s diseases of Ear, Nose and Throat, Volume I, IVth Edition. London C william Clowes & Sons 1984,665–674.
Randolph VH, Valleys A. Spiro RH. Strong GW, Huvos A.G., Wittee RE. Combination therapy of advanced head and neck.Cancer 1978; 41:460–467.
Steven F. Vogal, Barry H Kaplan—Chemotherapy of Advanced head and neck Cancer with Methotrexete, Bleomycin and Cis-platinum in an effective outpatient schedule.Cancer 1979; 44: 26–31.
Sarraf MA— Chemotherapy Strategies in Squaous cell Carcinoma of the Head and neck, RCC Critical reviews inOncology/Hematology 1984; 4: 323–3349.
Wittes RE, Head, Neck Monogram New York. Head Johonson, Bristol, Myers company, 1979/1980.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Saksena, A.K., Bhalla, A.S., Agrawal, S.R. et al. Initial response with methotrexate in advanced head and neck cancer. Indian J Otolaryngol 39, 22–25 (1987). https://doi.org/10.1007/BF02994242
Issue Date:
DOI: https://doi.org/10.1007/BF02994242